Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
EOM Shows Awareness of Issues, but Provides No Resources, Says COA’s Nicolas Ferreyros
The Enhancing Oncology Model is trying to address a number of the systemic challenges oncology faces without giving practices the tools and resources they need, said Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance.
Dose Adjustment Considerations in Patients With Chronic Kidney Disease: Dr Linda Awdishu
For patients with chronic kidney disease, dose adjustments for other medications requires coordination with other specialists to maintain treatment efficacy, explained Linda Awdishu, PharmD, FASN, professor and division head of clinical pharmacy at the University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences.
Dr Laura Denby: Long Noncoding RNA Is a Good Biomarker for Acute Kidney Injury
Smaller noncoding RNA is being used in clinical practice and as knowledge grows of long noncoding RNA, use of it should follow, explained Laura Denby, PhD, Kidney Research UK Senior Fellow, senior lecturer and principal investigator in the Centre for Cardiovascular Science at the University of Edinburgh.
Amivantamab Plus Lazertinib Improved PFS for EGFR-Mutated Advanced NSCLC
MARIPOSA demonstrated the combination reduced risk of progression or death by 30% compared with osimertinib. MARIPOSA-2 found amivantamab plus chemotherapy and amivantamab plus chemotherapy and lazertinib also improved progression-free survival (PFS) over chemotherapy after progression on osimertinib.
Trastuzumab Deruxtecan Demonstrates Efficacy Reducing Brain Metastases in HER2m NSCLC
Regardless of presence of brain metastases, patients with HER2-mutant (HER2m) non–small cell lung cancer (NSCLC) showed systemic responses to trastuzumab deruxtecan. In addition, the therapy showed intracranial efficacy to reduce the size of brain metastases.
Adding Adjuvant Nivolumab Builds on Standard of Care for Resectable NSCLC
The results of CheckMate 77T showcase the improved event-free survival for patients with resectable non–small cell lung cancer who receive nivolumab in both the neoadjuvant and adjuvant setting and may have practice-changing implications.
Overcoming the Efficacy-Effectiveness Gap in Cancer Therapy Research
With stringent criteria, randomized controlled trials are the cornerstone of cancer intervention research, but the result is they do not represent the majority of patients, which leads to a gap between the efficacy seen in trials and the effectiveness in the real-world setting.
Christine Pfaff on Ensuring Patient Access to Affordable Treatments
To ensure patients are getting timely access to their treatments, there needs to be better collaboration between payers and providers, said Christine Pfaff, RPh, senior regional director of operations, American Oncology Network.
Patient, Provider Education and Payer Management Can Improve Biosimilar Uptake: Dr Bincy Abraham
Biosimilars are becoming more common as more launch on the market in the United States, but patient and provider education can help speed uptake of these products, explained Bincy Abraham, MD, Houston Methodist – Weill Cornell.
Novel Approaches to Head and Neck Cancer at Vanderbilt Ingram Cancer Center
Speakers at an Institute for Value-Based Medicine event with Vanderbilt University Medical Center highlighted the novel therapies and techniques being used to improve outcomes for patients with head and neck cancer.